Funding for this research was provided by:
Gilead Sciences (Förderprogramm Infektiologie 2017)
Received: 4 July 2020
Accepted: 18 October 2020
First Online: 30 October 2020
Ethics approval and consent to participate
: Informed consent was obtained from participants and the ethical committee of the University of Frankfurt approved the study protocol (vote #452/16). The study was performed according to the Declaration of Helsinki.
: All authors approved the final version of the manuscript.
: MMM: Speaking fees from AbbVie and Alnylam, travel support from AbbVie, Gilead and Intercept, all unrelated to the submitted work. The study was supported by a research grant from Gilead to MMM as a part of the “Förderprogramm Infektiologie 2017”. VTM: Travel support from AbbVie and Gilead unrelated to the submitted work. KS: Travel support from AbbVie unrelated to the submitted work. SZ: Speaking and/or consulting fees from AbbVie, Bristol-Myers Squibb, Falk, Gilead, Janssen, and Merck/MSD all unrelated to the submitted work. CML: Speaker fees from AbbVie, Gilead, MSD, Norgine and travel support from AbbVie, and Gilead, all unrelated to the submitted work. SR, AM, JK, and RS declare that they have no competing interests.